Published in Ann Surg on July 01, 2002
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med (2009) 1.67
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg (2005) 1.60
Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer (2009) 1.44
Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis (2005) 1.17
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer (2009) 1.08
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer (2007) 1.07
A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. Ann Surg (2007) 1.02
Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer: treatment outcomes and analysis of prognostic factors. Cancer Res Treat (2012) 0.93
Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis. Radiat Oncol J (2013) 0.89
Tumor regression grades: can they influence rectal cancer therapy decision tree? Int J Surg Oncol (2013) 0.89
T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer. Eur Radiol (2012) 0.89
Factors associated with local recurrence after neoadjuvant chemoradiation with total mesorectal excision for rectal cancer. World J Surg (2009) 0.89
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer (2005) 0.89
Rectal cancer treatment: improving the picture. World J Gastroenterol (2007) 0.89
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis (2007) 0.88
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol (2015) 0.87
Mucinous adenocarcinoma of the rectum: a poor candidate for neo-adjuvant chemoradiation? J Gastrointest Oncol (2014) 0.85
High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol (2015) 0.84
Prognostic value of tumor shrinkage versus fragmentation following radiochemotherapy and surgery for rectal cancer. Virchows Arch (2015) 0.83
Complementary use of local excision and transanal endoscopic microsurgery for rectal cancer after neoadjuvant chemoradiation. Surg Endosc (2006) 0.82
Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol (2012) 0.81
Surgical training on rectal cancer surgery: do supervised senior residents differ from consultants in outcomes? Int J Colorectal Dis (2013) 0.81
Preoperative radiochemotherapy in t3 operable low rectal cancers: a gold standard? World J Surg (2010) 0.80
Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis (2005) 0.80
Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol (2014) 0.79
Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. Oncotarget (2014) 0.78
A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer (2016) 0.78
Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation. BMC Clin Pathol (2012) 0.77
Clinical impact of tumor regression grade after preoperative chemoradiation for locally advanced rectal cancer: subset analyses in lymph node negative patients. J Korean Soc Coloproctol (2011) 0.77
Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol (2016) 0.76
Colorectal Cancer Association of Canada consensus meeting: raising the standards of care for early-stage rectal cancer. Curr Oncol (2009) 0.76
A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy. Oncotarget (2016) 0.75
Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiat Oncol (2006) 0.75
Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome. J Gastrointest Oncol (2016) 0.75
Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience. Curr Oncol (2017) 0.75
The pathologist's role in rectal cancer patient assessments. Clin Colon Rectal Surg (2007) 0.75
Preoperative Chemoradiation in Locally Advanced Rectal Cancer: Efficacy and Safety. Gastroenterology Res (2015) 0.75
Adjuvant chemotherapy for rectal cancer: Is it needed? World J Clin Oncol (2015) 0.75
Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. Int J Colorectal Dis (2009) 0.75
Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med (1997) 9.99
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA (1990) 5.77
Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol (1999) 2.67
Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys (1999) 2.29
Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys (1995) 2.03
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol (1992) 1.98
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg (1995) 1.90
Experience with CHART. Int J Radiat Oncol Biol Phys (1991) 1.70
Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys (1998) 1.70
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum (1997) 1.41
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum (2000) 1.32
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res (1995) 1.29
Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys (1997) 1.20
Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg (1999) 1.15
Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys (2000) 1.10
Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys (1998) 1.09
Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol (1995) 1.06
Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol (1997) 1.02
Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol (1994) 1.00
High dose preoperative irradiation for cancer of the rectum, 1976-1988. Int J Radiat Oncol Biol Phys (1991) 0.98
Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol (2000) 0.97
Prognostic factors in patients with locally advanced rectal adenocarcinoma treated with preoperative radiotherapy and surgery. World J Surg (1999) 0.93
Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg (1997) 0.90
The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol Biol Phys (1995) 0.86
Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. J Clin Oncol (1998) 0.83
Altered fractionation in radiotherapy. Tumori (1998) 0.79
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology (2009) 3.66
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA (2005) 3.46
Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology (2013) 3.45
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg (2009) 2.93
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology (2014) 2.73
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol (2003) 2.69
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol (2004) 2.66
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med (2003) 2.62
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol (2007) 2.53
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum (2004) 2.52
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging (1999) 2.43
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol (2005) 2.43
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol (2013) 2.43
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther (2008) 2.42
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol (2007) 2.41
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol (2002) 2.39
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
A simple algorithm to predict incident kidney disease. Arch Intern Med (2008) 2.36
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 2.33
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab (2005) 2.30
Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery (2009) 2.29
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol (2012) 2.26
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med (2006) 2.24
Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg (2008) 2.21
Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg (2005) 2.19
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst (2005) 2.19
The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 2.18
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A (2007) 2.17
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg (2003) 2.16
Results after pancreatic resection for metastatic lesions. Ann Surg Oncol (2002) 2.15
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol (2005) 2.12
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett (2006) 2.12
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res (2004) 2.07
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Have the changes in treatment of rectal cancer made a significant difference to our patients? Oncology (Williston Park) (2011) 2.06
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05